New directions for drug discovery by Spedding, Michael
he discovery and development of one new drug
costs around $800 million (taking failures into account)
and takes an average of 10 to 12 years.This degree of
investment,with such a late return on this investment,is
unparalleled in human activity.
Despite this investment,some areas of great therapeutic
need do not have optimal treatments—acute stroke and
Alzheimer’s disease,as well as other central nervous sys-
tem (CNS) disorders.There are no drugs registered for
the treatment of acute stroke,which is an area of great
therapeutic need,being the third-highest cause of mor-
tality and the second-highest cause of morbidity.
Nevertheless,there are distinct methodological reasons
in the clinical trials which can preclude demonstrating
efficacy in stroke under many circumstances.
1Another
area in which the pharmaceutical industry has failed to
revolutionize therapy has been in the treatment of
Alzheimer’s disease. However, preventive therapy by
addressing hypertension using angiotensin-converting
enzyme inhibitors (perindopril, in the PROGRESS
study) has shown marked reduction in the incidence of
stroke, and also of dementia and cognitive decline.
2,3
Antidepressant drugs with higher efficacy and fewer side
effects are much needed.
Effective drug discovery requires drug targets for ther-
apeutic intervention which are pivotal points for the dis-
ease process, and up until now these have not been
clearly identified for stroke (with the possible exception
of tissue plasminogen activator for very early interven-
tion) or Alzheimer’s disease.
Background
Only 35 new compounds were registered with the Food
and Drug Administration (FDA) in 2003 despite a
research expenditure by the major pharmaceutical firms
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Modern drug discovery demands an integrative approach,
using many different technologies, but ultimately based
on an understanding of the pathophysiology of the dis-
ease state to be treated. Targeting drugs at the main
pathophysiological process is the key to success. This issue
needs to be addressed with the multiple screening systems
available, which can be used to find new leads.
© 2006, LLS SAS Dialogues Clin Neurosci. 2006;8:295-301.of 33 billion dollars (Figure 1).Part of these costs are due
to the costs of failure.Figure 2 shows the fate of a sam-
ple of 121 drugs put into phase 1 clinical trials by British
pharmaceutical companies. The results are edifying.
Although some drugs failed because of toxicological
problems or metabolic issues,or were even stopped for
commercial reasons,the major reason for failure was lack
of efficacy.The drugs were stopped because they did not
work.This may occur for several reasons.
First,the original hypothesis may be wrong,and the end
result is a useful experiment,albeit a very expensive one.
Second,and this is perhaps just as likely,the animal mod-
els may not represent the tests used in phase I and phase
II clinical trials—it is also possible that the tests used in
phase I and II do not represent the true patient response.
Indeed,of the 340 compounds entering phase I per year,
four out of five fail, and even when registration is
achieved,less than half of the compounds recoup their
development costs.The failure of drugs to work in the
clinical setting (lack of efficacy due either to the concept
not working,or to the animal models or the clinical mod-
els not responding to the patients’ needs) is a key area
for improvement.
Third,increasing safety requirements discourages risk.
This is particularly the case for CNS-active drugs which
may have cardiovascular side effects (effects on electro-
cardiographic [ECG] QTc intervals for example). It
remains a truism that no drug can be effective without
having some measure of risk.
However, it is now possible to have high-throughput
screens for safety,and to do a better job of selecting com-
pounds at an early stage.
The difficulties faced by a drug discoverer are shown by the
sequence below.First,he or she must find the optimal struc-
ture/activity,then exclude structure/activity at other sites:
1.Definition of structure/activity at site of action
2.Exclusion of structure/activity at cytochromes
3.Exclusion of structure/activity—mutagenicity
4.Exclusion of structure/activity—cardiac QTc
5.Start of toxicity studies.
Fourth,there is the realization of the increasing complex-
ity of biological systems. Although there may be only
25 000 to 30 000 genes, many of which are drug targets
(Figure 3), the gene products are much more complex
because of alternative splicing,mRNA editing,receptor
dimerization,functional trafficking (where drugs acting at
the same receptor may have different effects) and the mul-
tiple post-translational controls and accessory proteins.
New technological opportunities
In vitro screening
Screening on recombinant proteins has proven to be
immensely powerful, and can provide new leads from
high-throughput screening on a scale which would be
impossible with other technologies.Now the target pro-
teins may even be crystallized,with the drug,or even with
fragments of the drug,and the crystals analyzed to define
the conformational changes induced in the target by dif-
ferent drugs.The throughput of this technology is such
that entire chemical series can be analyzed for their
direct effects on the protein of interest.Thus,hundreds
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Figure 1. Research budget (billion $) and total number of US drug
registrations in 2003.
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Figure 2. Reasons for stopping clinical development of 121 com-
pounds in clinical trials carried out by seven British com-
panies. PK, pharmacokinetics
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50of thousands of compounds can be tested at the cellular
target in a few months,and the “hits”can then be chem-
ically optimized to make new metabolically stable drugs.
(Figure 3).Different conformational states during cellu-
lar activation,particularly in the presence of accessory
proteins, may easily change a singe hydrogen bond or
electrostatic attraction,changing affinity.Indeed,it must
be pointed out that one additional hydrogen bond
between the compound and the target can change the
affinity thirty-fold.This complexity may induce inade-
quate responses to predict therapeutic efficacy.As com-
pound selection is the crucial issue,we have argued that,
after preliminary screens in recombinant systems, and
following exclusion of inappropriate compounds (for
metabolic or safety reasons), the selection of the final
compound to proceed onto development should take
place in pathophysiological models, and preferably, if
breakthrough compounds are looked for,in novel patho-
physiological models. However, this means a major
investment in screening in animal models.
In vivo screening 
Animal models are often the limiting factor in research
(particularly for cognitive issues),and finding staff skilled
in their handling is not easy. Previous drugs have been
tested for in the established models,and the way to test
benzodiazepine anxiolytics is to use the classic anxiety
screening models,defined by diazepam.However,novel
drugs working in new ways may need new models.Thus,
compounds should be selected using a model of patho-
physiological conditions.However,this needs skilled phar-
macologists
4 with an integrative vision of pathophysiology.
How are new drugs discovered?
New drugs may be discovered in very many ways,but dis-
covery nearly always involves tight collaborations
between chemists and pharmacologists,who must iden-
tify the cellular and genetic factors important in patho-
physiology,produce appropriate hypotheses,and design
new test systems.Screening new molecules can be done
in a number of ways.
Target identification
Ideally,the target should be the cause of a specific dis-
ease which can be targeted on a molecular level.There
has been immense progress made in defining the recep-
tor systems in the human genome,by analogy to existing
7-transmembrane receptors. This marks a unique
moment in science,because many targets are becoming
known.Lists of these receptors have been produced (eg,
ref 5).Furthermore,new targets remain to be discovered,
and the existing targets are known to have many differ-
ent forms (alternative splicing, messenger ribonucleic
acid (mRNA) editing,single-nucleotide polymorphisms,
etc) which may allow selective targeting of disease states.
The bioinformatics industry provides an immensely pow-
erful tool to scientists,and many of these data are in the
public domain.
Target validation
A crucial issue is to validate the target, in animal and
preferably in human models.This is critical, because of
the high cost of discovering a new drug for a target and
performing the clinical experiment to find out whether
the new drug works in a disease state in man.As there
are tens of thousands of potential targets,target valida-
tion is a crucial issue. Fortunately, transgenic models
may help in this regard,but their predictivity is only rel-
ative.
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Figure 3. Signaling genes in the human genome.
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A lead compound is usually selected by high-throughput
screening of compound collections,or libraries (Figure 4).
These compound libraries may consist of thousands, or
hundreds of thousands, of compounds, built up by the
pharmaceutical company over the years.Virtual screens
can now be performed by modeling the interactions of the
target with virtual libraries consisting of all the compounds
which are commercially available—the best compounds
can then be selected for screening. The “hits” or com-
pounds which are active in the first round of screening are
then optimized so that they possess the properties needed
in a new drug.Testing is then done on each of these mole-
cules to confirm its effect on the drug target.
Lead optimization
Lead optimization compares the properties of various
lead compounds,allowing selection of the compound or
compounds with the greatest potential to be developed
into safe and effective medicines.The metabolism is opti-
mized in high-throughput screens to produce compounds
which retain their activity at the target of interest,while
being metabolically stable and well absorbed.
Drug testing in humans
Testing an investigational new drug requires submission
of all the information about the drug for permission to
administer to healthy volunteers or patients. Not only
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Figure 4. Screening of compound libraries: main pathway-dedicated platforms. GPC, G protein-coupled (Figure courtesy of Olivier
Nosjean and Jean Boutin, Servier research).
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Radio-ligandregulatory authorities,but also institutional or indepen-
dent review boards (IRB) or ethical advisory boards
approve the experimental protocol,well as the informed
consent documents signed by the volunteers.
The clinical testing of the drug passes through Phase I,
Phase II,and Phase III clinical studies.In each successive
phase,increasing numbers of patients are tested,but the
success or failure of the drug (see Figure 2) depends not
only on its mode of action,but also on the good method-
ological quality of the testing schedule used in the clinic.
Phase I clinical studies 
Phase I studies must verify the safety and tolerability of
the new drug in volunteers,showing the maximal tolerated
dose,and how it is absorbed,distributed,metabolized,and
excreted.This phase takes 6 months to a year.Healthy vol-
unteers are administered the drug acutely and then chron-
ically.The hypothesis of action may be tested pharmaco-
logically with indexes of brain penetration,brain imaging,
and electroencephalogram (EEG).However,it must be
borne in mind that healthy individuals may not react in the
same way as patients. Some drugs cannot be tested in
healthy volunteers (eg,in oncology).
Phase II clinical studies
Phase II studies are a critical research area designed to
show effectiveness,define dose-response for the critical
phase III approval studies,and demonstrate a measure
of safety in the patient population.This phase of devel-
opment generally takes from 1 to 3 years with several
hundred patients.It is here that an appropriate choice of
drug effectiveness criteria for drug effectiveness,linked
to animal models,yet providing a realistic test of the drug
in the patient population,can make a real difference.
Phase III clinical studies
Phase III studies show effectiveness and safety in ran-
domized and blinded clinical trials involving thousands
of patients.This phase can take 2 to 5 years, and is the
most expensive clinical testing phase.
New Drug Application/Marketing Authorization 
A New Drug Application (NDA),in the US,or Marketing
Authorization (MA),in Europe,documents the safety and
efficacy of the proposed drug,and the applications contain
all the reports from the drug development process.At the
end of phase III,the evidence proving efficacy and safety
are submitted.The approval process can take 1 to 2 years,
followed by post-marketing surveillance and extension of
the therapeutic indications and patient populations.
Fast-tracking
Several regulatory issues may be seen as opportunities.
Fast tracking for very urgent therapeutic needs, such as
treatment for acquired immune deficiency syndrome
(AIDS),has been introduced by the FDA.Furthermore,
the FDA have issued guidelines on pharmacogenetic sub-
typing of patient populations (responders,patients at risk
for side effects,rapid metabolizers,etc).
Partnership
Modern drug discovery and development depends on a
constant partnership between the actors in the project,in
the many disciplines which are involved.The partnership
between industry and academia is a critical issue,because
basic research can lead to many unexpected break-
throughs,of which the researcher may not appreciate the
industrial and medical importance.It is correct that finan-
cial return should be associated with inventiveness.
However,the fewer industrial partners there are (as in
France),the fewer local industrial partners there are for
startup biotechnology companies.There is thus a delicate
balance between support of pharmaceutical companies
and small biotechnology companies.As the main indus-
trial experience (to avoid the pitfalls shown in Figure 2
for example) is located in pharmaceutical companies,this
pragmatic feedback and review is an essential part of the
health of the local industrial environment.It is also essen-
tial that research remains very medically oriented,
because the patients' needs come first.Partnership with
clinicians and top medical teams is therefore also a key
element for success. However, all of the stages of drug
discovery remain an experiment,and must be designed
as such.After the initial selection process which finds the
drug,the only thing which does not change in the devel-
opment process is the molecule;all the others—the sci-
entists, sometimes even the therapeutic area—may
change.However,the molecule can do no more or less
than on the day when it is chosen,which is why the tests
which select the molecule are so important.
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Key points for definition of new ways 
forward in psychiatric disorders
It is important to define the specific nodes or switch-
points which are modified by disease processes and suit-
able for therapeutic intervention.These can be at several
levels,such as:
1.Molecular—the multiple intracellular signaling cas-
cades have key nodal points which can be targetted.
Cancer drugs are targetted at key points,and now
the same situation is being extended into CNS
research,where drugs for bipolar disorder,such as
lithium,may interact with key signaling molecules
such as glycogen synthase kinase 3 (GSK3).
2.Epigenetic changes where the genes expressed relate
to the past history of the idividual. Furthermore,
many gene products are modified by alternative splic-
ing or mRNA editing which can change the function
of key proteins in pathophysiological conditions.
3.Cell plasticity.Neurotrophins and cytokines have
major effects on cell plasticity and integrity.Many
genes can interact within the neurotrophic signal-
ing cascades,and these are major points for thera-
peutic interventions.For example,we have shown
that brain-derived neurotrophic factor (BDNF),the
key neurotrophin involved in activity-dependent
resculpting of neuronal networks,can also change
the respiratory coupling efficiency of mitochondria,
indicating a new way forward in the links between
cellular activity and coupled metabolism.
6
4.The neurotransmitters involved in modulating brain
systems are well defined,and still represent sources
of drug discovery (noradrenaline,5-HT,dopamine,
etc).However,the multiple states of receptors and
their signaling pathways warn against oversimplifi-
cation.
7
5.Chronobiological issues are important in resetting
biological rhythms,and may be even more impor-
tant than previously thought. The finding that
agomelatine, a melatonin agonist and 5-HT2C
antagonist,can be an effective antidepressant with
a low side-effect potential
8,9 reconfirms the interest
in chronobiological systems,because their dysreg-
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Table I. What are the main factors influencing success in drug discovery
processes, and how can research output be improved?
• 1. Resources. Resources are critical, and all programs must
have access to major molecular resources for screening for
drug discovery. 
• 2. Access to a rapid drug development program, with clini-
cal tests which are tightly related to the animal tests. Thus,
feedback to discovery scientists can be rapid to optimize
discovery and to ensure that researchers do not continue
to work on hypotheses which do not stand up in the clinic.
• 3. Approaches and strategies. This is a critical issue for suc-
cess, and requires medicalized research, in association with
the specialized resources. Reverse engineering animal mod-
els from our new knowledge of brain systems in disease
states will better reflect pathophysiological situations and
allow selection of new drugs.
• 4. Quality/creativity. The quality, application, and creativity
of the scientists involved, together with the relevance of
the approaches and strategies, are key factors for success.
However, there are few measures, other than past records,
which can be quantified by objective criteria (other than
publications, but these are not always related to drug dis-
covery capacity).
• 5. Outside research. Having access to a large network of
academic contacts is crucial to increasing the number of
ideas processed and increasing throughput.
Figure 5. The impact of stress on neuroplasticity may be a novel
target for drugs in psychiatry, as stress inhibits plasticity
in hippocampal and prefrontal cortex circuits while
increasing plasticity in the circuits dealing with emotion
(amygdala, prefrontal cortex).
10ulation is a common feature of ageing and psychi-
atric disorders.
6.Cell firing on specific nodal points.The systems in
the brain are becoming well defined,and it is now
possible to intervene on brain switch-points,which
may be deregulated.These can be quantified elec-
trophysiologically,or by microdialysis of the main
neurotransmitters,or by brain imaging techniques.
7.Neuronal networks for brain functions (eg,the main
systems involved in cognition,decision,and emotiv-
ity and fear (prefrontal cortex, amygdala, hip-
pocampus,Figure 5).An example of research in this
area is the finding that stress blocks long-term poten-
tiation (LTP, a measure of plasticity) in the hip-
pocampal to ventromedial prefrontal cortex,
11 and
these effects are reversed acutely by an atypical anti-
depressant,tianeptine.McEwen’s group have shown
that these acute effects change into effects on den-
dritic arborization.
12 Furthermore,there is now proof
of concept that this pathway is of critical importance
for depression because Mayberg’s group
13 have
implanted electrodes into the white matter behind
Cg25 (the equivalent in man of the ventromedial
prefrontal cortex in rodents) and found immediate
antidepressant effects in patients who had been
entirely treatment-resistant.Targetting these brain
areas therefore opens up new perspectives in drug
discovery for depression.Furthermore,reingineer-
ing animal models to study these brain areas will
allow the selection of new classes of molecule. ❏
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Nuevos caminos para el descubrimiento de
fármacos
El descubrimiento moderno de fármacos requiere
de una aproximación integradora en que se utilizan
diversas tecnologías, pero en último término se
basa en la comprensión de la fisiopatología del
curso clínico de la enfermedad para que así pueda
ser tratada. La clave del éxito está en conseguir fár-
macos que apunten al proceso fisiopatológico cen-
tral. Este tema necesita ser abordado con los múlti-
ples sistemas de exploración disponibles, los que
pueden utilizarse para encontrar nuevas posibles
moléculas.
Nouvelles directions dans la découverte des
médicaments
La découverte moderne de médicaments demande
une approche intégrée, utilisant des technologies
variées; elle est fondée sur la compréhension de la
physiopathologie de la maladie à traiter. La clé du
succès est de cibler les médicaments qui agissent sur
le principal processus physiopathologique. Cette
question doit être abordée à l’aide des nombreux
systèmes de sélection des molécules existants afin
de trouver de nouvelles pistes.
REFERENCES
1. Spedding M. Reasons why stroke trials underestimate the neuroprotec-
tive effects of drugs. Stroke. 2002;33,324-325.
2. The PROGRESS Collaborative Group. Effects of blood pressure lowering
with perindopril and indapamide therapy on dementia and cognitive
decline in patients with cerebrovascular disease. Arch Intern Med.
2003:163:1069-1075.
3. Dufouil C, Chalmers J, Coskun O, et al. Effects of blood pressure lower-
ing on cerebral white matter hyperintensities in patients with stroke.
Circulation. 2005;112:1644-1650.
4. Collis MG. Integrative pharmacology and drug discovery - is the tide
turning? Nature Drug Discovery. 2006:5,377-379.
5. Foord SM, Bonner TI, Neubig RR, et al. International Union of
Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev.
2005;2:279-288.
6. Markham A, Cameron I, Franklin P, Spedding M. BDNF increases mito-
chondrial respiratory coupling, and glutamate metabolism, at complex I,
but not complex II. Eur J Neurosci. 2004;20:1189-1196.
7. Kenakin T. New concepts in drug discovery: collateral efficacy and per-
missive antagonism.  Nature Drug Discovery. 2005;4:919-927.
8. Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine,
a melatoninergic agonist and selective 5-HT2c antagonist, in the treatment
of major depressive disorder: a placebo-controlled dose range study. Int Clin
Psychopharmacol. 2002;17:239-247.
9. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the
treatment of major depressive disorder. Eur Neuropsychopharmacol.
2006;16:93-100.
10. Spedding M, Jay T, Costa e Silva J, Perret L. A pathophysiological para-
digm for the therapy of psychiatric disease. Nature Drug Discovery.
2005;4:467-476.
11.Rocher C, Spedding M, Munoz C, Jay T. Acute stress-induced changes
in cortical synaptic plasticity: interactions with antidepressants. Cereb Cortex.
2004;14, 224-229.
12.McEwen BS, Olié JP. Neurobiology of mood, anxiety and emotions, as
revealed by studies of a unique antidepressant: tianeptine. Mol Psych.
2005;10:525-537.
13.Mayberg HS, Lozano A, Voon V, et al. Deep brain stimulation for treat-
ment resistant depression. Neuron. 2005;45:651-660.